Abstract
In patients with acute myelogenous leukemia, published guidelines and treatment recommendations are usually the basis for starting the work-up process for allogeneic transplant. However, only consistent recommendations would allow a standardized clinical practice. We conducted a comprehensive systematic literature search to identify and evaluate the best available evidence from controlled clinical trials. In addition, recommendations given by leading organizations in the USA and Europe were analyzed. The following aspects were selected for systematic comparison: factors for risk assessment and categorization, role of type of donor, significance of allogeneic transplant in first or second complete remission and in relapse/progressive disease; and role of reduced intensity conditioning regimens. In conclusion, the recommendations for the use of allogeneic transplant given by the literature and by published guidelines are inconsistent and will need clarification.
Original language | English |
---|---|
Pages (from-to) | 444-457 |
Number of pages | 14 |
Journal | Leukemia and Lymphoma |
Volume | 52 |
Issue number | 3 |
Early online date | 16 Feb 2011 |
DOIs | |
Publication status | Published - Mar 2011 |
Keywords
- Adult
- Controlled Clinical Trials as Topic
- Donor Selection
- Health Planning Guidelines
- Humans
- Internationality
- Leukemia, Myeloid, Acute
- Patient Selection
- Practice Guidelines as Topic
- Stem Cell Transplantation
- Transplantation, Homologous